Oncotarget · 2017 · 34 citations · 29 references
MedicineHematologyOncologyHematopathologyMolecular OncologyOncogenesCancer CytogeneticsClinical CytogeneticsHematologic MalignanciesHematopoietic NeoplasmsMolecular CytogeneticsAcute LeukemiasAcute Myeloid Leukemia BiologyAcute Myeloid Leukemia TherapyCytogenetics In Hematologic DiseaseLeukemia CytogeneticsLeukemia PathologyOncogenic Ras MutationsRas Signaling
// Jing-Dong Zhou 1, 3, * , Dong-Ming Yao 2, 3, * , Xi-Xi Li 1, 3, * , Ting-Juan Zhang 1, 3 , Wei Zhang 1, 3 , Ji-Chun Ma 2, 3 , Hong Guo 2, 3 , Zhao-Qun Deng 2, 3 , Jiang Lin 2, 3 and Jun Qian 1, 3 1 Department of Hematology, Affiliated People’s Hospital of Jiangsu University, Zhenjiang, Jiangsu, People’s Republic of China 2 Laboratory Center, Affiliated People’s Hospital of Jiangsu University, Zhenjiang, Jiangsu, People’s Republic of China 3 The Key Laboratory of Precision Diagnosis and Treatment of Zhenjiang City, Zhenjiang, Jiangsu, People’s Republic of China * These authors have contributed equally to this work Correspondence to: Jun Qian, email: qianjun0007@hotmail.com Jiang Lin, email: linjiangmail@sina.com Keywords: RAS , expression, mutation, prognosis, acute myeloid leukemia Received: April 25, 2017 Accepted: June 29, 2017 Published: August 02, 2017 ABSTRACT The prognostic value of RAS mutations has been systematically investigated in acute myeloid leukemia (AML). However, clinical significance of RAS expressions in AML remains poorly determined. To explore the clinical significance, we analyzed KRAS and NRAS expressions in 143 de novo AML patients by real-time quantitative PCR. KRAS and NRAS expressions were significantly up-regulated in AML patients. KRAS and NRAS mutations were identified in 4% (6/143) and 8% (12/143) of these patients, respectively. However, no significant association was observed between RAS mutations and expressions. High KRAS expression was associated with older age, higher white blood cells, and a tendency of higher platelets, whereas high NRAS expression was only correlated with older age. Complete remission (CR) rate and overall survival of AML patients were adversely affected by KRAS overexpression, but not NRAS overexpression. Multivariate analysis revealed that KRAS acted as an independent prognostic predictor in cytogenetically normal AML (CN-AML). Moreover, the prognostic value of KRAS expression was validated using the published data from Gene Expression Omnibus datasets. In the follow-up patients, KRAS expression rather than NRAS expression in CR time tended to decrease compared to newly diagnosis time, and both KRAS and NRAS expressions were significantly increased when in relapse time. Our findings revealed that RAS overexpression and mutations were common events in AML with potential therapeutic target value. KRAS overexpression independent of RAS mutations conferred an adverse prognosis in CN-AML.
29
David Grimwade, Robert K. Hills, Anthony V. Moorman et al. · Blood · 2010 · 2K citations · Full text
Life Sciences, Hematology, Oncology +16
Guido Marcucci, Kati Maharry, Yue-Zhong Wu et al. · Journal of Clinical Oncology · 2010 · 764 citations · Full text
Medicine, Hematology, Oncology +17
FLT3, RAS, and TP53 mutations in elderly patients with acute myeloid leukemia
Derek L. Stirewalt, Kenneth J. Kopecky, Soheil Meshinchi et al. · Blood · 2001 · 440 citations
Oncogenic KRAS Confers Chemoresistance by Upregulating NRF2
Shue Wang, Seyed Javad Moghaddam, Aikseng Ooi et al. · Cancer Research · 2014 · 292 citations · Full text
Medicine, Cancer Biology, Oncology +17